{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:19:12Z","timestamp":1775863152783,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11523-023-00988-0","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:01:46Z","timestamp":1695200506000},"page":"727-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences"],"prefix":"10.1007","volume":"18","author":[{"given":"Jacqueline C.","family":"Barrientos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayed O.","family":"Ayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senxi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley M.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna M.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon B.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy L.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-0921","authenticated-orcid":false,"given":"Jing-Zhou","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"1","key":"988_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"988_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.clml.2011.07.002","volume":"11","author":"PJ Shenoy","year":"2011","unstructured":"Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011;11(6):498\u2013506. https:\/\/doi.org\/10.1016\/j.clml.2011.07.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"988_CR3","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1182\/bloodadvances.2022008643","volume":"7","author":"AS Kittai","year":"2023","unstructured":"Kittai AS, Huang Y, Bhat SA, Paskett ED, Rogers KA, Barrientos J, et al. Racial and socioeconomic disparities in CLL\/SLL: analysis of SEER data from 2006\u20132019. Blood Adv. 2023;7(11):2575\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2022008643.","journal-title":"Blood Adv"},{"issue":"25","key":"988_CR4","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849\u201361.\u00a0https:\/\/doi.org\/10.1200\/JCO.19.03355.","journal-title":"J Clin Oncol"},{"issue":"16","key":"988_CR5","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1200\/JCO.2022.40.16_suppl.7508","volume":"40","author":"V Vardell","year":"2022","unstructured":"Vardell V, Ermann DA, Shah H, Fitzgerald L, Hu B, Stephens DM. Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic lymphoma [abstract 7508]. J Clin Oncol. 2022;40(16):7508. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7508.","journal-title":"J Clin Oncol"},{"issue":"32","key":"988_CR6","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/jco.22.00504","volume":"40","author":"M Casey","year":"2022","unstructured":"Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM, et al. Are pivotal clinical trials for drugs approved for leukemias and multiple myeloma representative of the population at risk? J Clin Oncol. 2022;40(32):3719\u201329.\u00a0https:\/\/doi.org\/10.1200\/jco.22.00504.","journal-title":"J Clin Oncol"},{"issue":"4","key":"988_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171\u20135. https:\/\/doi.org\/10.1038\/s41375-021-01485-x.","journal-title":"Leukemia"},{"issue":"3","key":"988_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1400376.","journal-title":"N Engl J Med"},{"issue":"2","key":"988_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos JC, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112\u201320. https:\/\/doi.org\/10.1182\/blood.2021014960.","journal-title":"Blood"},{"issue":"5","key":"988_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1817073.","journal-title":"N Engl J Med"},{"issue":"12","key":"988_CR11","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268\u201373. https:\/\/doi.org\/10.1002\/cncr.30596.","journal-title":"Cancer"},{"issue":"3","key":"988_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.clml.2019.10.009","volume":"20","author":"AR Mato","year":"2020","unstructured":"Mato AR, Barrientos JC, Ghosh N, Pagel JM, Brander DM, Gutierrez M, et al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry. Clin Lymphoma Myeloma Leuk. 2020;20(3):174-83.e3. https:\/\/doi.org\/10.1016\/j.clml.2019.10.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"988_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/bloodadvances.2019001145","volume":"4","author":"A Mato","year":"2020","unstructured":"Mato A, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, et al. The connect CLL registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020;4(7):1407\u201318. https:\/\/doi.org\/10.1182\/bloodadvances.2019001145.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"988_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2019-122434","volume":"134","author":"CR Frei","year":"2019","unstructured":"Frei CR, Le H, McHugh D, Elesinmogun C, Galley S, Franklin K, et al. Treatment patterns and outcomes of 1205 patients on novel agents in the US Veterans Health Administration (VHA) System: results from the largest retrospective EMR and chart review study in the real-world setting [abstract]. Blood. 2019;134(Suppl 1):795. https:\/\/doi.org\/10.1182\/blood-2019-122434.","journal-title":"Blood"},{"issue":"1","key":"988_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","volume":"13","author":"C Hardy-Abeloos","year":"2020","unstructured":"Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020;13(1):66. https:\/\/doi.org\/10.1186\/s13045-020-00870-w.","journal-title":"J Hematol Oncol"},{"issue":"25","key":"988_CR16","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"988_CR17","first-page":"4060","volume":"130","author":"JP Sharman","year":"2017","unstructured":"Sharman JP, Black-Shinn JL, Clark J, Bitman B. Understanding ibrutinib treatment discontinuation patterns for chronic lymphocytic leukemia [abstract]. Blood. 2017;130(suppl 1):4060.","journal-title":"Blood"},{"issue":"11","key":"988_CR18","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","volume":"60","author":"PJ Hampel","year":"2019","unstructured":"Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60(11):2712\u20139. https:\/\/doi.org\/10.1080\/10428194.2019.1602268.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"988_CR19","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1002\/cam4.2998","volume":"9","author":"SA Parikh","year":"2020","unstructured":"Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, et al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020;9(10):3390\u20139. https:\/\/doi.org\/10.1002\/cam4.2998.","journal-title":"Cancer Med"},{"key":"988_CR20","unstructured":"Imbruvica [package insert]. Sunnyvale, CA, Horsham, PA: Pharmacyclics, Janssen Biotech, Inc.; 2022."},{"issue":"12","key":"988_CR21","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1080\/10428194.2019.1620944","volume":"60","author":"M Dimou","year":"2019","unstructured":"Dimou M, Iliakis T, Pardalis V, Bitsani C, Vassilakopoulos TP, Angelopoulou M, et al. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma. 2019;60(12):2939\u201345. https:\/\/doi.org\/10.1080\/10428194.2019.1620944.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"988_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10): e191870. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870.","journal-title":"JAMA Oncol"},{"issue":"17","key":"988_CR23","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1002\/cncr.28030","volume":"119","author":"L Falchi","year":"2013","unstructured":"Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, et al. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer. 2013;119(17):3177\u201385. https:\/\/doi.org\/10.1002\/cncr.28030.","journal-title":"Cancer"},{"issue":"35","key":"988_CR24","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.2217\/fon-2021-0964","volume":"17","author":"JZ Hou","year":"2021","unstructured":"Hou JZ, Ryan K, Du S, Fang B, Marks S, Page R, et al. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncol. 2021;17(35):4959\u201369. https:\/\/doi.org\/10.2217\/fon-2021-0964.","journal-title":"Future Oncol"},{"issue":"2","key":"988_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clml.2017.11.010","volume":"18","author":"A Mato","year":"2018","unstructured":"Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, et al. Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization\/cytogenetics: a real-world clinical experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018;18(2):114-24.e2. https:\/\/doi.org\/10.1016\/j.clml.2017.11.010.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"988_CR26","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1080\/10428194.2018.1554862","volume":"60","author":"OS Akhtar","year":"2019","unstructured":"Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2019;60(7):1650\u20135. https:\/\/doi.org\/10.1080\/10428194.2018.1554862.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"988_CR27","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199\u2013205. https:\/\/doi.org\/10.1182\/blood-2016-05-716977.","journal-title":"Blood"},{"issue":"5","key":"988_CR28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","volume":"28","author":"AR Mato","year":"2017","unstructured":"Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx031.","journal-title":"Ann Oncol"},{"issue":"8","key":"988_CR29","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2022.2045597","volume":"63","author":"J Collins","year":"2022","unstructured":"Collins J, Stump SE, Heiling H, Muir M, Deal A, Proco D, et al. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2022;63(8):1823\u201330. https:\/\/doi.org\/10.1080\/10428194.2022.2045597.","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"988_CR30","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"key":"988_CR31","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma version 2.2022: National Comprehensive Cancer Network; 2021 [updated 18 January 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00988-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:18:28Z","timestamp":1695460708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00988-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00988-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"3 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by AstraZeneca. Medical writing and editorial support was provided by Claire Jarvis, PhD, and Maria Ali, PhD, of Peloton Advantage, LLC (Parsippany, NJ, USA), an OPEN Health company, and funded by AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jacqueline C. Barrientos has received research support from Oncternal, VelosBio, AstraZeneca, and Pharmacyclics\/AbbVie and has served on advisory boards for BeiGene, Pharmacyclics\/AbbVie, TG Therapeutics, and MEI Pharma. Ayed O. Ayed has served on an advisory board for AstraZeneca. Agnes Cha has received a research grant (paid to institution) from AstraZeneca. Senxi Du, Bruno Fang, Ryan Hall, Stanley M. Marks, Eileen Peng, Sharon B. Winters, and Percy L. Yeung have no disclosures to report. Joanna M. Rhodes has received research support from Oncternal, VelosBio, Pharmacyclics\/AbbVie, and LOXO Oncology and has served as a consultant for BeiGene, Pharmacyclics\/AbbVie, TG Therapeutics, MorphoSys, Verastem, ADC Therapeutics, Genentech, SeaGen, GenMab, Janssen, Epizyme, and AstraZeneca. Kellie Ryan is an employee of AstraZeneca. Jing-Zhou Hou has received a research grant (paid to institution) from AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was exempt from ethical review by the Western Institutional Review Board (WA, USA) prior to starting data collection. This observational study was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki, the International Conference on Harmonisation\u2019s Guidelines for Good Clinical Practice, the Guidelines for Good Pharmacoepidemiology Practices and applicable legislation on noninterventional studies and\/or observational studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at . Data for studies directly listed on Vivli can be requested through Vivli at . Data for studies not listed on Vivli could be requested through Vivli at . AstraZeneca Vivli member page is also available outlining further details: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SMM and KR designed the study. JCB, AC, BF, RH, SMM, and JMR served as study investigators. AC, SD, RH, SMM, JMR, SBW, and PLY collected and assembled the data. JCB, SMM, and KR analyzed the data. JCB, AOA, SMM, EP, and KR interpreted the data. SMM, KR, and PLY prepared the manuscript. All authors reviewed and revised the manuscript. All authors provided final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}